Shots:

• The US FDA has granted RPD and ODD to LX2006 for the treatment of FA. The company plans to start a P-I/II clinical trial of LX2006 in patients with cardiomyopathy associated with FA in 2021
• Additionally- if BLA for LX2006 is approved- a company may be eligible to receive PRV that may be sold or transferred
• The company focuses to advance clinical programs to commercialization & maintain an ongoing research collaboration with Weill Cornell to foster the company’s pre-clinical pipeline. LX2006 (IV) is an AAV-mediated gene therapy encoding the human frataxin gene

  | Ref: Globe Newswire | Image: Yahoo Finance